Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
Clin Mol Hepatol 2022;28(3):425-472. Published online July 1, 2022
The global burden of chronic liver disease (CLD) is substantial. Due to the limited indication of and accessibility to antiviral therapy in viral hepatitis and lack of effective pharmacological treatment in nonalcoholic fatty liver disease, the beneficial effects of antidiabetics and non–antidiabetics in clinical practice have been continuously investigated in patients with CLD. In this narrative review, we focused on non-antidiabetic drugs, including ursodeoxycholic acid, silymarin, dimethyl4,4’-dimethoxy-5,6,5’,6’-dimethylenedixoybiphenyl-2,2’-dicarboxylate, L-ornithine L-aspartate, branched chain amino acids, statin, probiotics, vitamin E, and aspirin, and summarized their beneficial effects in CLD. Based on the antioxidant, anti-inflammatory properties, and regulatory functions in glucose or lipid metabolism, several non–antidiabetic drugs have shown beneficial effects in improving liver histology, aminotransferase level, and metabolic parameters and reducing risks of hepatocellular carcinoma and mortality, without significant safety concerns, in patients with CLD. Although the effect as the centerpiece management in patients with CLD is not robust, the use of these non-antidiabetic drugs might be potentially beneficial as an adjuvant or combined treatment strategy.
Citations
Citations to this article as recorded by
CYP4A14-PPARα axis serves as a therapeutic target for ursodeoxycholic acid in ameliorating high-fat diet-induced MASLD Bing Li, Pengjun Zhong, Xueling Zhang, Chengguo Li, Min Luan, Yanlin Chen, Lei Chen, Wu Li, Rihui Wu The Journal of Nutritional Biochemistry.2026; 147: 110138. CrossRef
An in vitro 3D spheroid model with liver steatosis and fibrosis on microwell arrays for drug efficacy evaluation Jiamin Chen, Ping Wang, Zhanpeng Li, Jieyi Wu, Fang Tang, Niao Yang, Bohong Cen, Cuiyin Xie, Yufan Yang, Ziyan Yang, Chuwen Zhang, Xiangcao Yao, Zhongyuan Xu Journal of Biotechnology.2025; 399: 153. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
Pharmacotherapy in metabolic-dysfunction-associated steatotic liver disease: an updated review of the past, present and a promising future Sunetra Mondal, Amarta Shankar Chowdhury, Rajat Deb, Debmalya Sanyal Diabetology International.2025; 16(4): 678. CrossRef
Polymer-engineered delivery systems for Schisandra lignans: A review of advances in hepatic-targeted therapy Jia Zhou, Jiyuan Zhang, Jinzhuan Xu, Man Zhang, Yuanxing Huang, Zhengli Zhou, Hexinchen Tian, Jing Huang, Jianqing Peng, Runbin Sun, Yi Chen, Zipeng Gong International Journal of Biological Macromolecules.2025; 323: 147083. CrossRef
Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’ Dong Hyun Kim, Hye Won Lee Alimentary Pharmacology & Therapeutics.2025; 62(9): 954. CrossRef
Modulation of Amomum tsao-ko on lipid metabolism and gut microbiota in high-fat diet-fed mice with NAFLD Zezhu Du, Lijun Yu, Jinya Dong, Linxian Shan, Jun He, Yan Shen, Yanmei Li, Xiuli Lu, Shengjie Duan, Jianyang Fu, Xiaocui Du, Yunfei Ge, Ruijuan Yang, Chongye Fang Journal of Agriculture and Food Research.2025; 24: 102379. CrossRef
Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review Hafiza Madiha Jaffar, Fahad Al‐Asmari, Faima Atta Khan, Muhammad Abdul Rahim, Eliasse Zongo Food Science & Nutrition.2024; 12(5): 3097. CrossRef
The additive effect of herbal medicines on lifestyle modification in the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis Myung-Ho Kim, Subin Ahn, Nayeon Hur, Seung-Yun Oh, Chang-Gue Son Frontiers in Pharmacology.2024;[Epub] CrossRef
Association between ursodeoxycholic acid use and COVID-19 in individuals with chronic liver disease: a nationwide case-control study in South Korea Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Virology Journal.2024;[Epub] CrossRef
Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks Amani Elshaer, Blanca C. Lizaola-Mayo Life.2024; 14(12): 1701. CrossRef
Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha Cureus.2023;[Epub] CrossRef
ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Won Young Tak, Young-Oh Kweon, Soo Young Park, Seung Up Kim Clinical Gastroenterology and Hepatology.2023; 21(9): 2278. CrossRef
Case 9: A 62-Year-Old Woman With Jaundice and General Weakness Hee Sun Cho, Ji Won Han, Ji Hoon Kim, Heechul Nam, Pil Soo Sung, Si Hyun Bae Journal of Korean Medical Science.2023;[Epub] CrossRef
Visión actual sobre el diagnóstico y los cuidados integrales en la encefalopatía hepática F. Higuera-de-la-Tijera, J.A. Velarde-Ruiz Velasco, R.H. Raña-Garibay, G.E. Castro-Narro, J.M. Abdo-Francis, R. Moreno-Alcántar, J.L. Pérez-Hernández, A. Torre, R. Contreras-Omaña, A. Cano-Contreras, M. Castillo-Barradas, J. Pérez-Escobar, J.M. Aldana-Led Revista de Gastroenterología de México.2023; 88(2): 155. CrossRef
Current vision on diagnosis and comprehensive care in hepatic encephalopathy F. Higuera-de-la-Tijera, J.A. Velarde-Ruiz Velasco, R.H. Raña-Garibay, G.E. Castro-Narro, J.M. Abdo-Francis, R. Moreno-Alcántar, J.L. Pérez-Hernández, A. Torre, R. Contreras-Omaña, A. Cano-Contreras, M. Castillo-Barradas, J. Pérez-Escobar, J.M. Aldana-Led Revista de Gastroenterología de México (English Edition).2023; 88(2): 155. CrossRef
Multiple Hepatic Artery Pseudoaneurysms With Eosinophilia Mun Young Cho, Pil Soo Sung, Sung Hak Lee Gastroenterology.2023; 165(4): 843. CrossRef
Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Hee Cheon, Jong In Yook, Man-Deuk Kim, Dong Jin Joo, Seung Up Kim Cell Communication and Signaling.2023;[Epub] CrossRef
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen Clinical and Molecular Hepatology.2022; 28(4): 841. CrossRef
CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice Rongrong Tan, Jiayang Li, Lu Liu, Qian Wu, Lei Fan, Ningning Ma, Chuwei Yu, Henglei Lu, Xuemei Zhang, Jing Chen, Likun Gong, Jin Ren International Journal of Molecular Sciences.2022; 23(24): 15931. CrossRef
Genotype–Phenotype Association in ABCC2 Exon 18 Missense Mutation Leading to Dubin–Johnson Syndrome: A Case Report Ji-Hoon Kim, Min-Woo Kang, Sangmi Kim, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung International Journal of Molecular Sciences.2022; 23(24): 16168. CrossRef
First
Prev
